Blood & Clots Series: What is the optimal antithrombotic strategy for atrial fibrillation post-PCI?

In Blood & Clots, Medical Concepts by Vinai BhagirathLeave a Comment

All the content from the Blood & Clots series can be found here.

CanMEDS Roles addressed: Medical Expert

Main Messages

  •  P2Y12 inhibition is important for the first 1-6 months after PCI insertion, and may have ongoing benefits up to 12 months or longer.
  •  Addition of anticoagulant to antiplatelet therapy increases the risk of bleeding, but reduces the risk of stroke.
  •  Use of an anticoagulant plus P2Y12 inhibitor is preferable to anticoagulant plus dual antiplatelet therapy, because of reduced bleeding risk.

Case Description

You are seeing a 72-year-old woman with a history of atrial fibrillation (AF), and additional stroke risk factors of hypertension and diabetes mellitus type 2. She had previously been treated with warfarin for stroke prevention, but recently suffered an ST elevation MI, and underwent percutaneous coronary intervention (PCI) with a drug-eluting stent placed in the left anterior descending artery (LAD). She has received loading of ASA and clopidogrel at the time of PCI, but the post-PCI antithrombotic strategy has not been decided.

She has never had a bleeding complication in the past. Her INR control has been good. She has no other relevant medical co-morbidities.

What antithrombotic medications would you recommend to this patient to prevent MI/stent occlusion and stroke, while also minimizing the risk of bleeding? What would you do if this patient returned with GI bleeding 2 weeks after PCI.

Main Text

Patients with AF have an approximately twofold increase in risk of MI compared to age-adjusted controls, 1 with an approximately 1% per year rate of MI seen in recent AF trials 2 3. Dual antiplatelet therapy with ASA and a P2Y12 receptor inhibitor (e.g. clopidogrel, prasugrel, or ticagrelor)  is considered standard of care for patients receiving PCI, since it has been shown to decrease the risk of recurrent ischemic events, particularly stent thrombosis 4 5 6 .  Stent thrombosis is increased in patients who discontinue P2Y12 inhibitor within 1 month of stent placement, and is associated with a high risk of mortality; however, dual antiplatelet therapy increases the risk of bleeding 7. Bleeding is an important complication that is associated with an increase in mortality, tending to counteract benefits in risk of ischemic events 8 9.

Dual antiplatelet therapy is not as effective as anticoagulant for prevention of stroke in AF 10.  The risk of bleeding when anticoagulation is added to antiplatelet therapy is particularly high, with more than 25% of patients who receive warfarin in addition to dual antiplatelet therapy experiencing a bleeding event requiring medical attention within three years after PCI 11. A number of studies have demonstrated a lower risk of bleeding when using alternative antithrombotic strategies post-PCI. The WOEST trial compared dual antiplatelets + anticoagulant (triple therapy) vs. single agent clopidogrel + anticoagulant (dual therapy) in patients on warfarin after PCI 12. The bleeding rate was decreased markedly with dual therapy, with no signal for increased thrombotic events, although the trial was not powered to detect differences in thrombotic outcomes. Of note, the target INR was 2.0 in this trial. The PIONEER AF-PCI trial compared very low dose rivaroxaban (2.5mg twice-daily) plus dual antiplatelet therapy vs. reduced dose rivaroxaban (10-15mg daily) plus P2Y12 antagonist vs. warfarin plus dual antiplatelet therapy 11. The 2.5mg twice-daily rivaroxaban arm had therapy switched to rivaroxaban 15mg daily and aspirin after 1, 6, or 12 months, while the warfarin arms switched to warfarin plus aspirin after 1, 6, or 12 months (non-randomized). For both rivaroxaban arms, the hazard ratio for bleeding outcomes was around 0.6 compared to the warfarin arm, while there was no suggestion of increase in the risk of thrombotic outcomes, although again the trial was not powered to detect differences in thrombosis. The RE-DUAL PCI trial similarly compared the standard warfarin plus dual antiplatelet therapy against dabigatran at 110 or 150mg daily plus P2Y12 inhibitor, and found a halving in the risk of clinically relevant bleeding, with a finding of non-inferiority for a thrombotic composite endpoint 13.

In summary, recent trials have consistently found a decrease in bleeding with the use of anticoagulant plus P2Y12 inhibitor compared to triple therapy in patients with atrial fibrillation and indication for anticoagulation after PCI. The use of a DOAC such as rivaroxaban 15mg daily or dabigatran at a therapeutic dose, or warfarin with careful monitoring and INR target at the lower end of the therapeutic range, all appear to be reasonable options when combined with P2Y12 inhibitor alone after PCI. Because the above trials were not powered for thrombotic outcomes, some clinicians will use a short course (1 month) of triple therapy before switching to dual therapy.

The optimal duration of P2Y12 inhibition after PCI is unclear. In patients with no indication for anticoagulation, current guidelines suggest dual antiplatelet therapy after PCI for 12 months, with shorter or longer duration considered reasonable 4 14. PIONEER AF-PCI did stratify patients by duration of P2Y12 inhibitor, but was not powered to detect differences in thrombotic outcomes11.

Guidelines

The 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy 15 suggest triple therapy with aspirin plus clopidogrel plus reduced dose/intensity anticoagulation for patients with AF and CHADS2 score ≥1 or age >65, who undergo PCI for ACS or high-risk elective PCI. Discontinuation of the aspirin is considered reasonable anywhere from 1 day to 6 months after PCI, and the timing can be guided by the perceived risk of recurrent MI (strong recommendation, moderate quality evidence). The clopidogrel can be continued for up to 12 months after PCI, (weak recommendation, moderate quality evidence) and the anticoagulant dose should return to the usual dose after the clopidogrel is discontinued 15.

Case Conclusion

The patient is switched to dabigatran 150mg bid and clopidogrel 75mg daily after the PCI. This strategy was felt to minimize the risk of bleeding, while maintaining efficacy at stroke prevention and likely also for prevention of recurrent MI.

2 weeks later she returns to ER with a GI bleed. Consideration is given to reversal of dabigatran and discontinuation of clopidogrel. Since she is hemodynamically stable, her clopidogrel is continued, but the dabigatran is stopped. This strategy is felt to minimize risk of stent thrombosis (within the first month after PCI), and also to reduce the risk of exacerbating bleeding. A bleeding colonic polyp is found on colonoscopy, which is removed. 72 hours later, the dabigatran is re-initiated. Consideration was given to switching to an anticoagulant with a lower risk of GI bleeding, but since the cause of bleeding was felt to have been identified and resolved, dabigatran was restarted.

All the content from the Blood & Clots series can be found here.

This post was reviewed by Brent Thoma, Mark Woodcroft and uploaded by Rebecca Dang.

References

1.
Soliman EZ, Safford MM, Muntner P, et al. Atrial Fibrillation and the Risk of Myocardial Infarction. JAMA Intern Med. 2014;174(1):107. doi:10.1001/jamainternmed.2013.11912
2.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883-891. doi:10.1056/nejmoa1009638
3.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361(12):1139-1151. doi:10.1056/nejmoa0905561
4.
Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology. 2016;67(10):1235-1250. doi:10.1016/j.jacc.2015.10.005
5.
Mehta S, Yusuf S, Peters R, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-533. [PubMed]
6.
Sabatine MS. Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With FibrinolyticsThe PCI-CLARITY Study. JAMA. 2005;294(10):1224. doi:10.1001/jama.294.10.1224
7.
Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med. 2014;371(23):2155-2166. doi:10.1056/nejmoa1409312
8.
Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. N Engl J Med. 2006;354(14):1464-1476. doi:10.1056/nejmoa055443
9.
Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal. 2011;32(15):1854-1864. doi:10.1093/eurheartj/ehr204
10.
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. The Lancet. 2006;367(9526):1903-1912. doi:10.1016/s0140-6736(06)68845-4
11.
Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375(25):2423-2434. doi:10.1056/nejmoa1611594
12.
Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. The Lancet. 2013;381(9872):1107-1115. doi:10.1016/s0140-6736(12)62177-1
13.
Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377(16):1513-1524. doi:10.1056/nejmoa1708454
14.
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2017;39(2):119-177. doi:10.1093/eurheartj/ehx393
15.
Mehta SR, Bainey KR, Cantor WJ, et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Canadian Journal of Cardiology. 2018;34(3):214-233. doi:10.1016/j.cjca.2017.12.012
(Visited 267 times, 1 visits today)
Vinai Bhagirath

Vinai Bhagirath

Vinai Bhagirath is a Hematologist with a special interest in Thrombosis. He is an Assistant Professor at McMaster University, and the Director of McMaster's Adult Thrombosis Medicine Area of Focused Competence Training Program. His research interests include optimal dosing of direct oral anticoagulants.